Form 4: Tango Therapeutics CEO Barbara Weber Sells Shares to Cover Tax Obligations

Tango Therapeutics CEO Barbara Weber sold shares of common stock on February 4th and 5th, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Barbara Weber, CEO of Tango Therapeutics, sold shares of the company's common stock on February 4th and 5th, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• On February 4th, 2025, 9,778 shares were sold at a weighted average price of $2.988 per share.
• On February 5th, 2025, 9,013 shares were sold at a weighted average price of $3.1614 per share.
• Following these transactions, Weber directly owns 1,622,251 shares of Tango Therapeutics common stock.
• The sales were automatic under a 'sell-to-cover' policy adopted by Tango Therapeutics and were not at Weber's discretion.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. It's important to consider the context of these sales, such as whether they are part of a pre-planned trading program or represent a significant change in the executive's holdings.

Stakeholder Impact

• The stock sales could have a minor, temporary impact on the stock price, but are unlikely to significantly affect stakeholders given the routine nature of the transactions.

Key Dates

Keywords

Tango Therapeutics, Barbara Weber, stock sale, Form 4, tax withholding, restricted stock units, TNGX, CEO